Medscape Conference Coverage, based on selected sessions at the:
American Diabetes Association (ADA) 68th Scientific Sessions
June 6 - 10, 2008, San Francisco, California
This activity is not sanctioned by, nor a part of, the American Diabetes Association. Conference news does not receive grant support and is produced independently.
Investigational Agents Appear to Reverse Type 1 Diabetes Disease ProcessThe combination of a potent specific anti-inflammatory agent plus an islet regeneration protein appears to cause formerly inactive islet cells, or perhaps new beta cells, to again produce insulin, researchers reported here this week during the 68th Annual Scientific Sessions of the American Diabetes Association.
Reuters Health, June 13, 2008
New DDP-4 Inhibitor Shows Safety, Efficacy in Type 2 DiabetesAlmost half of patients with type 2 diabetes poorly controlled with diet and exercise or other antidiabetic agents were able to reach target hemoglobin A1C levels of less than 7.0% with a new, highly selective dipeptidyl peptidase-IV (DDP-4) inhibitor, alogliptin (SYR-32, Takeda Pharmaceutical Co.).
Reuters Health, June 13, 2008
Twelve-Week Weight-Loss Program Shows Long-Term Success for DiabeticsResearchers at the Joslin Diabetes Center report that a 12-week weight-loss program they devised for patients with type 2 diabetes continues to have a positive, long-lasting effect on weight loss a year later, long after patients are off on their own.
Reuters Health, June 13, 2008
Safety Study Finds Glargine Not Associated With RetinopathyThe safety of the insulin analog glargine (Lantus, Sanofi-Aventis, Paris) was demonstrated in a 5-year post-marketing evaluation of the drug, in which there was no evidence of an increased risk of retinopathy with long-term glargine use.
One-Fourth of Lifelong Type 1 Diabetics May Still Produce Some InsulinJoslin Diabetes Center researchers report that a study of diabetic "medalists" -- individuals with type 1 diabetes for more than 50 years duration who have relatively few complications -- revealed that over 27% appeared to have the capacity to secrete insulin.
Reuters Health, June 10, 2008
Estimated Average Glucose Value Seen as New Yardstick for Diabetes ControlThe estimated average glucose (AG) value could become the "common language of physicians and their diabetic patients," investigators announced here during the 68th Annual Scientific Sessions of the American Diabetes Association.
Takeda New Diabetes Drug Seen Good but Not GreatA drug candidate critical to Takeda Pharmaceutical Co Ltd's mainstay diabetes franchise is expected to show sufficient promise to gain approval but may not be much better than a rival medicine from Merck & Co.
Reuters Health, June 5, 2008
Legal Disclaimer
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Diabetes Association. These materials and the related activity are not sanctioned by the American Diabetes Association or the commercial supporter of the conference and do not constitute an official part of that conference.
